Exner M - Search Results

1

Homocysteine promotes the LDL oxidase activity of ceruloplasmin.

Exner M, Hermann M, Hofbauer R, Hartmann B, Kapiotis S, Gmeiner B. Exner M, et al. FEBS Lett. 2002 Nov 20;531(3):402-6. doi: 10.1016/s0014-5793(02)03571-8. FEBS Lett. 2002. PMID: 12435583 Free article.

2

Free and peptide-bound DOPA can inhibit initiation of low density lipoprotein oxidation.

Exner M, Hermann M, Hofbauer R, Kapiotis S, Gmeiner BM. Exner M, et al. Free Radic Res. 2003 Nov;37(11):1147-56. doi: 10.1080/10715760310001595766. Free Radic Res. 2003. PMID: 14703726

3

Salicylate inhibits LDL oxidation initiated by superoxide/nitric oxide radicals.

Hermann M, Kapiotis S, Hofbauer R, Exner M, Seelos C, Held I, Gmeiner B. Hermann M, et al. Among authors: exner m. FEBS Lett. 1999 Feb 19;445(1):212-4. doi: 10.1016/s0014-5793(99)00043-5. FEBS Lett. 1999. PMID: 10069403 Free article.

4

The salicylate metabolite gentisic acid, but not the parent drug, inhibits glucose autoxidation-mediated atherogenic modification of low density lipoprotein.

Exner M, Hermann M, Hofbauer R, Kapiotis S, Speiser W, Held I, Seelos C, Gmeiner BM. Exner M, et al. FEBS Lett. 2000 Mar 17;470(1):47-50. doi: 10.1016/s0014-5793(00)01289-8. FEBS Lett. 2000. PMID: 10722843 Free article.

5

p-Hydroxyphenylacetaldehyde, the major product of tyrosine oxidation by the activated myeloperoxidase system can act as an antioxidant in LDL.

Exner M, Alt E, Hermann M, Hofbauer R, Kapiotis S, Quehenberger P, Speiser W, Minar E, Gmeiner B. Exner M, et al. FEBS Lett. 2001 Feb 9;490(1-2):28-31. doi: 10.1016/s0014-5793(01)02131-7. FEBS Lett. 2001. PMID: 11172805 Free article.

6

Semicarbazide-sensitive amine oxidase catalyzes endothelial cell-mediated low density lipoprotein oxidation.

Exner M, Hermann M, Hofbauer R, Kapiotis S, Quehenberger P, Speiser W, Held I, Gmeiner BM. Exner M, et al. Cardiovasc Res. 2001 Jun;50(3):583-8. doi: 10.1016/s0008-6363(01)00208-5. Cardiovasc Res. 2001. PMID: 11376634

7

The main components of St John's Wort inhibit low-density lipoprotein atherogenic modification: a beneficial "side effect" of an OTC antidepressant drug?

Laggner H, Schreier S, Hermann M, Exner M, Mühl A, Gmeiner BM, Kapiotis S. Laggner H, et al. Among authors: exner m. Free Radic Res. 2007 Feb;41(2):234-41. doi: 10.1080/10715760600978831. Free Radic Res. 2007. PMID: 17364950

8

Hydrogen sulphide: a novel physiological inhibitor of LDL atherogenic modification by HOCl.

Laggner H, Muellner MK, Schreier S, Sturm B, Hermann M, Exner M, Gmeiner BM, Kapiotis S. Laggner H, et al. Among authors: exner m. Free Radic Res. 2007 Jul;41(7):741-7. doi: 10.1080/10715760701263265. Free Radic Res. 2007. PMID: 17577734

9

Hydrogen sulfide destroys lipid hydroperoxides in oxidized LDL.

Muellner MK, Schreier SM, Laggner H, Hermann M, Esterbauer H, Exner M, Gmeiner BM, Kapiotis S. Muellner MK, et al. Among authors: exner m. Biochem J. 2009 May 13;420(2):277-81. doi: 10.1042/BJ20082421. Biochem J. 2009. PMID: 19265508

10

S-carbamoylation impairs the oxidant scavenging activity of cysteine: its possible impact on increased LDL modification in uraemia.

Schreier SM, Steinkellner H, Jirovetz L, Hermann M, Exner M, Gmeiner BM, Kapiotis S, Laggner H. Schreier SM, et al. Among authors: exner m. Biochimie. 2011 Apr;93(4):772-7. doi: 10.1016/j.biochi.2011.01.007. Epub 2011 Jan 26. Biochimie. 2011. PMID: 21277933

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

460 results

Search Page

Filters